For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral GLP-1 pill being studied for the treatment of type 2 diabetes and obesity, ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

Healthify plans to expand partnerships with weight-loss drugmakers, leveraging its new deal with Novo Nordisk to enhance ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...